Over 1 in 3 people affected by neurological conditions, the leading cause of illness and disability worldwide $169 Bn Global CNS market size forecast, 2027 3 billion people worldwide were living with a neurological condition CNS disorders made up 15% of all product-focussed investment transactions in four of the past five years CNS is predicted to become the #2 therapy area for Pharma investment behind oncology that remains #1

Over 1 in 3 people affected by neurological conditions, the leading cause of illness and disability worldwide $169 Bn Global CNS market size forecast, 2027 3 billion people worldwide were living with a neurological condition CNS disorders made up 15% of all product-focussed investment transactions in four of the past five years CNS is predicted to become the #2 therapy area for Pharma investment behind oncology that remains #1

Data-driven in bio modelling for CNS therapeutics.

Data-driven in bio modelling for CNS therapeutics.

CNS disease is dynamic across stage, region, vasculature, patient age, and cell type.

CNS disease is dynamic across stage, region, vasculature, patient age, and cell type.

ASSEMBLIFY generates multimodal, human datasets that reveal disease-specific contexts to identify and validate molecular targets and progress therapeutic programs with greater translational confidence.

How ASSEMBLIFY generates the data flywheel

  • A naturally forming, self-perfusing blood–brain barrier (BBB) and neurovascular unit (NVU).
  • A modular brain-compartment designed to interrogate cell, region- and circuit-level biology.
  • Personalisation using patient tissue and blood to capture immune/vascular context.
  • Relevant human brain cell-type involvement (neurons, astrocytes, microglia, and vascular components).
  • Clinical collaborations.
Decision-driving Whole Brain Data Flywheel

Partnership focus

We are currently looking for partnerships in:

We are currently looking for partnerships in:

  • Small molecules, chemical compounds
    Does the asset reach the right brain cells, engage the target, and show specificity/selectivity? Brain tissue distribution, target engagement, compartment-level activity.

  • Gene therapy & delivery (AAV and beyond)
    Which capsids/carriers deliver where, in which context, and with what cellular profile? Tropism and compartment readouts, delivery performance across NVU/BBB; cell-type involvement.
  • Conjugates & targeted delivery
    Can asset delivery and engagement be made specific, measurable, and clinically relevant? Shuttle/Transporter validation readouts linked to BBB/NVU biology.
  • Medical devices, brain-computer-interface, brain implant development
    Does the device or implant interrogate and modulate CNS cells or circuits as intended?

End-to-end discovery and validation

From context-specific biology through target validation to evidence and decisions:

From context-specific biology through target validation to evidence and decisions:

  • Generate hypotheses from context-specific biology (disease stage, region, neurovascular involvement, and cell-type contributions).
  • Resolve mechanism: receptors, pathways, and causal drivers supported by multimodal readouts.
  • Validate actionability in a real time neurovascular setting to confirm where and when assets and mechanisms matter.
  • Produce modality-ready data packages that support program decisions (small molecules, viral capsids, carrier technologies, reservoir computing/BCI)

Our Company

Assemblify is a brain drug screening platform spin-out from the University of Leeds, led by world-leading researchers. With a novel off-the-shelf approach, functioning age-relevant models and blood brain barrier-prototypes validated through compelling pilot data, we are committed to turning our ambition into a transformative reality.

Core Team

CMO Ryan Matthew

CMO Ryan Mathew

Associate Professor & Honorary Consultant Neurosurgeon at Leeds. He holds a PhD in Stem Cells and Cerebral Organoid Modelling of Brain Tumours. He has a translational science interest in biological disease modelling, with a focus in neuroscience.

CSO Heiko Wurdak

CSO Heiko Wurdak

Interdisciplinary scientist and Group Head with background in biochemistry, developmental biology/stem cells, chemical biology, and cancer research. His research experience spans from screening to molecular target identification and validation combined with complex disease model development with a focus on the brain.

Laboratory Head Sabrina Samuel

Laboratory Head Sabrina Samuel

Expert in Tissue on Chip and 3D tissue disease modelling.